- Home
- AMLX vs CRVS Comparison
AMLX vs CRVS Comparison
Compare AMLX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- CRVS
- Stock Information
- Founded
- AMLX 2014
- CRVS 2014
- Country
- AMLX United States
- CRVS United States
- Employees
- AMLX N/A
- CRVS N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- CRVS Health Care
- Exchange
- AMLX Nasdaq
- CRVS Nasdaq
- Market Cap
- AMLX 459.1M
- CRVS 305.4M
- IPO Year
- AMLX 2022
- CRVS 2016
- Fundamental
- Price
- AMLX $7.68
- CRVS $4.11
- Analyst Decision
- AMLX Strong Buy
- CRVS Strong Buy
- Analyst Count
- AMLX 8
- CRVS 4
- Target Price
- AMLX $11.00
- CRVS $15.00
- AVG Volume (30 Days)
- AMLX 2.1M
- CRVS 1.2M
- Earning Date
- AMLX 08-07-2025
- CRVS 08-05-2025
- Dividend Yield
- AMLX N/A
- CRVS N/A
- EPS Growth
- AMLX N/A
- CRVS N/A
- EPS
- AMLX N/A
- CRVS N/A
- Revenue
- AMLX N/A
- CRVS N/A
- Revenue This Year
- AMLX N/A
- CRVS N/A
- Revenue Next Year
- AMLX N/A
- CRVS N/A
- P/E Ratio
- AMLX N/A
- CRVS N/A
- Revenue Growth
- AMLX N/A
- CRVS N/A
- 52 Week Low
- AMLX $1.76
- CRVS $1.78
- 52 Week High
- AMLX $7.72
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AMLX 75.73
- CRVS 53.94
- Support Level
- AMLX $5.97
- CRVS $3.79
- Resistance Level
- AMLX $6.86
- CRVS $4.31
- Average True Range (ATR)
- AMLX 0.54
- CRVS 0.29
- MACD
- AMLX 0.13
- CRVS 0.00
- Stochastic Oscillator
- AMLX 98.29
- CRVS 72.64
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).